Drug Profile


Alternative Names: NPS 1506

Latest Information Update: 23 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Craniocerebral trauma; Major depressive disorder; Stroke

Most Recent Events

  • 24 Jan 2005 Suspended - Phase-I for Depression in USA (unspecified route)
  • 24 Feb 2004 Phase-I clinical trials in Depression in USA (unspecified route)
  • 20 Oct 2003 Preclinical trials in Depression in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top